JP7778095B2 - セレブロン結合化合物、その組成物及びそれによる治療方法 - Google Patents

セレブロン結合化合物、その組成物及びそれによる治療方法

Info

Publication number
JP7778095B2
JP7778095B2 JP2022579835A JP2022579835A JP7778095B2 JP 7778095 B2 JP7778095 B2 JP 7778095B2 JP 2022579835 A JP2022579835 A JP 2022579835A JP 2022579835 A JP2022579835 A JP 2022579835A JP 7778095 B2 JP7778095 B2 JP 7778095B2
Authority
JP
Japan
Prior art keywords
mmol
trans
cyclohexyl
thioxoimidazolidin
oxo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022579835A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531709A5 (https=
JP2023531709A (ja
Inventor
ディ アレキサンダー，マシュー
ディ コレア，マシュー
ダルビー，ディーパク
ヘザー シャロン グラント，バージニア
ハンセン，ジョシュア
サード，ロイ エル ハリス，ザ
ジェイ ホーン，エバン
ホアン，デフア
メイン，クリストファー
ノリス，スティーブン
プラントヴァン－クレニツキー，ヴェロニク
ジェイ サピエンザ，ジョン
テラニ，リダ
ダブリュー ホワイトフィールド，ブランドン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Corp
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of JP2023531709A publication Critical patent/JP2023531709A/ja
Publication of JP2023531709A5 publication Critical patent/JP2023531709A5/ja
Application granted granted Critical
Publication of JP7778095B2 publication Critical patent/JP7778095B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
JP2022579835A 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法 Active JP7778095B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063043612P 2020-06-24 2020-06-24
US63/043,612 2020-06-24
PCT/US2021/038625 WO2021262812A1 (en) 2020-06-24 2021-06-23 Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Publications (3)

Publication Number Publication Date
JP2023531709A JP2023531709A (ja) 2023-07-25
JP2023531709A5 JP2023531709A5 (https=) 2024-06-18
JP7778095B2 true JP7778095B2 (ja) 2025-12-01

Family

ID=79032406

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579835A Active JP7778095B2 (ja) 2020-06-24 2021-06-23 セレブロン結合化合物、その組成物及びそれによる治療方法

Country Status (9)

Country Link
US (2) US11739075B2 (https=)
EP (1) EP4171568B1 (https=)
JP (1) JP7778095B2 (https=)
KR (1) KR20230027213A (https=)
CN (1) CN115955979B (https=)
AR (1) AR122725A1 (https=)
ES (1) ES3048462T3 (https=)
TW (1) TW202216681A (https=)
WO (1) WO2021262812A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020405129A1 (en) 2019-12-19 2022-06-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
CR20220630A (es) 2020-05-09 2023-01-23 Arvinas Operations Inc Métodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificación que comprenden el mismo
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
WO2022262782A1 (zh) * 2021-06-17 2022-12-22 南京明德新药研发有限公司 戊二酰亚胺取代的异噁唑稠环化合物及其应用
JP2024534223A (ja) 2021-09-01 2024-09-18 シーザン ハイスーク ファーマシューティカル カンパニー リミテッド Ｂｃｌ－２ファミリータンパク質を分解する化合物及びその医薬的な応用
AU2023278399A1 (en) 2022-06-02 2024-12-19 Xizang Haisco Pharmaceutical Co., Ltd. Compound for inhibiting or degrading bcl6 and use thereof in pharmaceutics
TW202530189A (zh) 2023-09-29 2025-08-01 日商第一三共股份有限公司 ３－苯基丙基胺衍生物
TW202535392A (zh) 2023-12-08 2025-09-16 美商亞文納營運公司 使用雄性素受體降解劑治療脊髓延髓性肌肉萎縮

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483A (zh) 2006-03-09 2007-09-12 陈德桂 调节雄激素受体活性的乙内酰脲衍生物的组成及其应用
US20160214972A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20190076542A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110317192A (zh) 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7026484B2 (en) * 2001-02-23 2006-04-11 Ligand Pharmaceuticals Incorporated Tricyclic androgen receptor modulator compounds and methods
US6861432B2 (en) * 2001-11-23 2005-03-01 Schering Aktiengesellschaft Piperazine derivatives that destabilize androgen receptors
WO2008101030A1 (en) * 2007-02-13 2008-08-21 The Regents Of The University Of California Methods for amplifying steroid hormone effects
AR088082A1 (es) * 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
WO2015179438A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
CN113453681B (zh) 2018-12-19 2024-10-11 细胞基因公司 经取代的3-((3-氨基苯基)氨基)哌啶-2，6-二酮化合物、其组合物及使用它们的治疗方法
CN113473987B (zh) 2018-12-19 2024-09-03 细胞基因公司 被取代的3-((3-氨基苯基)氨基)哌啶-2,6-二酮化合物、其组合物和使用其的治疗方法
KR20230027214A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법
JP7778095B2 (ja) 2020-06-24 2025-12-01 セルジーン コーポレーション セレブロン結合化合物、その組成物及びそれによる治療方法
KR20230027066A (ko) 2020-06-24 2023-02-27 셀진 코포레이션 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101032483A (zh) 2006-03-09 2007-09-12 陈德桂 调节雄激素受体活性的乙内酰脲衍生物的组成及其应用
US20160214972A1 (en) 2015-01-20 2016-07-28 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US20190076542A1 (en) 2016-05-10 2019-03-14 C4 Theraprutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN110317192A (zh) 2018-03-28 2019-10-11 上海美志医药科技有限公司 一类具有降解雄激素受体活性的化合物

Also Published As

Publication number Publication date
CN115955979A (zh) 2023-04-11
EP4171568B1 (en) 2025-08-27
US11739075B2 (en) 2023-08-29
WO2021262812A1 (en) 2021-12-30
EP4171568A4 (en) 2024-07-24
EP4171568A1 (en) 2023-05-03
TW202216681A (zh) 2022-05-01
US12227490B2 (en) 2025-02-18
ES3048462T3 (en) 2025-12-10
CN115955979B (zh) 2025-12-05
US20210403453A1 (en) 2021-12-30
KR20230027213A (ko) 2023-02-27
JP2023531709A (ja) 2023-07-25
AR122725A1 (es) 2022-09-28
US20230348431A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7778095B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7781792B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP7781083B2 (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526191A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526182A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
JP2024526192A (ja) セレブロン結合化合物、その組成物及びそれによる治療方法
HK40091356B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091356A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357A (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith
HK40091357B (en) Cereblon binding compounds, compositions thereof, and methods of treatment therewith

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250430

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251028

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251118

R150 Certificate of patent or registration of utility model

Ref document number: 7778095

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150